Keen Vision Acquisition - Unit | 10-Q: FY2025 Q3 Revenue: USD 0
I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2025 Q3, the actual value is USD 0.
EBIT: As of FY2025 Q3, the actual value is USD -248.48 K.
Segment Revenue
- The company has not commenced any operations and will not generate operating revenues until after the completion of a Business Combination.
Operational Metrics
- Net income for the nine months ended September 30, 2025, was $1,499,692, compared to $6,600,651 for the same period in 2024.
- Net income for the three months ended September 30, 2025, was $373,466, compared to $1,559,923 for the same period in 2024.
Cash Flow
- Net cash used in operating activities for the nine months ended September 30, 2025, was - $664,463, compared to - $681,249 for the same period in 2024.
- Net cash provided by investing activities for the nine months ended September 30, 2025, was $16,457,732.
- Net cash used in financing activities for the nine months ended September 30, 2025, was - $15,831,937.
Unique Metrics
- Dividend income earned in investments held in Trust Account for the nine months ended September 30, 2025, was $2,111,544, compared to $5,596,106 for the same period in 2024.
Future Outlook and Strategy
- The company has entered into a merger agreement with Medera Inc., a clinical stage biopharmaceutical company, with the intention to effectuate a business combination.
- The company has extended the time to complete its business combination until November 27, 2025, with the possibility of further extensions.
- The company faces substantial doubt about its ability to continue as a going concern if a Business Combination is not consummated by November 27, 2025.
